Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ledipasvir/sofosbuvir plus ribavirin in chronic hepatitis C with advanced liver disease or post-liver transplant
2013-002802-30Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ledipasvir and ribavirin in hepatitis C virus infection, sponsored by Gilead Sciences. Primary endpoint: SVR12. Started Oct 2013; status: completed.
02
Drugs
ledipasvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2013-002802-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002802-30.